Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Addex Therapeutics Ltd (ADXN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
1.3200-0.0200 (-1.49%)
At close: 5:32PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3400
Open1.3400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.3200 - 1.3500
52 Week Range1.2950 - 2.6200
Volume4,942
Avg. Volume28,579
Market Cap45.038M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ADXN.SW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    • GlobeNewswire

      Addex to Present at the Investors’ Day hosted by Voxia Communication

      Geneva, Switzerland, October 6, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investors’ Day hosted by Voxia Communication (October 7, 2021). The event will take place at the Beau Rivage Hotel in Geneva. In his presentation, which is scheduled for Thursday, October 7, 2021, at 12:10 CEST, Mr Dyer will provide a corporate upd

    • GlobeNewswire

      Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors

      Geneva, Switzerland, October 4, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr Lütjens, Head of Discovery – Biology and Dr Rocher, Head of Discovery – Chemistry, will present today at the 10th International Meeting on Metabotropic Glutamate Receptors (October 1 - 6, 2021). Dr Paparin, Senior Manager – Chemistry, will be participating at the conference as well. In a first

    • GlobeNewswire

      Addex to Present at the Cantor Global Healthcare 2021 Conference

      Geneva, Switzerland, September 29, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Cantor Global Healthcare 2021 Conference (September 27 - 30, 2021). In his presentation, which is scheduled for Wednesday, September 29, 2021 at 08:00 EDT / 14:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The vide

    Advertisement
    Advertisement